Among antibodies proposed for direct inhibition of uPAR engagement with uPA, the humanized ATN-658 MoAb, inhibiting both metastasis and tumor proliferation in mouse models, also in combination with zolendronic acid, has emerged as a new promising tool for clinical trials (Mahmood et al., 2020). This evidence concerns the gene PLAUR and neoplasm.